

**Filed On Behalf Of:**

Novartis AG and LTS Lohmann Therapie-Systeme AG

**By:**

Raymond R. Mandra  
ExelonPatchIPR@fchs.com  
(212) 218-2100

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

**NOVEN PHARMACEUTICALS INC.,**  
Petitioner

v.

**NOVARTIS AG AND LTS LOHMANN THERAPIE-SYSTEME AG,**  
Patent Owners

---

*Inter Partes* Review No. 2014-00550

U.S. Patent 6,335,031

UNOPPOSED MOTION TO FILE CORRECTED AND SUPPLEMENTAL  
PATENT OWNERS' EXHIBITS AND CORRECTED EXHIBIT LIST

Patent Owners Novartis AG and LTS Lohmann Therapie-Systeme AG respectfully move the Board for leave to submit corrected Exhibits 2012, 2023, 2035, 2044, 2050, 2051 and supplemental Exhibit 2054 to their January 20, 2015 Patent Owner Response and for leave to submit amended Patent Owners' Exhibit List 3 as set forth below.

On January 27, 2015, Noven Pharmaceuticals ("Petitioner") served objections pursuant to 37 C.F.R § 42.64(b)(1) to all of Patent Owners' filed exhibits. Petitioner's objections included (i) general evidentiary objections and (ii) specific objections due to clerical and typographical errors addressed herein. On February 10, 2015, pursuant to 37 C.F.R § 42.64(b)(2), Patent Owners provided a list of corrections and supplemental evidence to address certain errors raised in Petitioner's objections. In a communication dated February 18, 2015, Petitioner agreed that the proposed corrections and supplemental evidence cured the defects to which they were addressed but maintained all remaining objections. Patent Owners have provided the corrected and supplemental exhibits and amended Exhibit List 3 to the Petitioner, and Petitioner has stated that it does not oppose this motion.

Patent Owners sought permission to file this motion, which was granted in an email from the Board on March 10, 2015.

To facilitate the Board’s review of this matter, Patent Owners seek permission to file the following exhibits and amended exhibit list to correct clerical and typographical errors:

**Exhibit 2012**

To correct the following clerical and typographical errors in paragraph 85 and Appendix A paragraph 1 of Exhibit 2012, Patent Owners provide the Supplemental Declaration of Alexander M. Klibanov, Ph.D., dated February 10, 2015, making the following corrections to Dr. Klibanov’s January 20, 2015 Declaration:

- Paragraph 85: Change “(Ex. 2040, USP XX (1979) at 1079; Ex. 2041, USP XXII (1989) at 624.)” to “(Ex. 2040, United States Pharmacopeia and National Formulary (USP 20-NF 15), Rockville, MD: United States Pharmacopeial Convention, 1980 at 624; Ex. 2041, United States Pharmacopeia and National Formulary (USP 22-NF 17), Rockville, MD: United States Pharmacopeial Convention, 1990 at 1079.)”
- Appendix A, Paragraph 1: Change “(Ex. 40, Rosin, col. 4, ll. 21-53.)” to “(Ex. 1008, Rosin, col. 4, ll. 21-53.)”

**Exhibits 2023, 2035, 2044 and 2050**

To address, in part, Petitioner’s objections, Patent Owners provide replacement exhibits 2023, 2035, 2044, and 2050 with associated cover pages.

Patent Owners request permission to file an amended Exhibit List 3 to clarify the entry for Exhibit 2023:

- Change “U.S. Pharmacopeial Convention, Revision Bulletin, Clonidine Transdermal System (Jan. 1, 2011)” to “U.S. Pharmacopeial Convention, Revision Bulletin, Clonidine Transdermal System (Jan. 1, 2011) *incorporated into* United States Pharmacopeia and National Formulary (USP 34-NF 29) Supplement 2, 5407-5410, Rockville, MD: United States Pharmacopeial Convention, 2011”

#### **Exhibits 2040 and 2041**

To address, in part, Petitioner’s objections to Exhibits 2040 and 2041, Patent Owners request permission to file an amended Exhibit List 3 with the following corrections:

- The entry for Exhibit 2040 change “The United States Pharmacopeia, 624-625 (20th ed., 1979) (Entry for Physostigmine Salicylate Injection)” to “United States Pharmacopeia and National Formulary (USP 20-NF 15), 624-625, Rockville, MD: United States Pharmacopeial Convention, 1980”
- The entry for Exhibit 2041 change “The United States Pharmacopeia, 1078-1079 (22nd ed., 1989) (Entry for Physostigmine Salicylate Injection)” to “United States Pharmacopeia and National Formulary (USP 22-NF 17),

1078-1079, Rockville, MD: United States Pharmacopeial Convention,  
1990”

**Exhibit 2047**

To address, in part, Petitioner’s objections to Exhibit 2047, Patent Owners provide the Declaration of Lisa Butler (supplemental Exhibit 2054), dated February 10, 2015.

**Exhibit 2051**

To address, in part, Petitioner’s objections to Exhibit 2051, Patent Owners provide a clean replacement copy of the exhibit.

Respectfully submitted,

Dated: March 11, 2015

/Raymond R. Mandra/  
Raymond R. Mandra  
Registration No. 34,382  
Lead Counsel for Patent Owner  
FITZPATRICK, CELLA, HARPER  
& SCINTO  
1290 Avenue of the Americas  
New York, NY 10104-3800  
Tel. 212-218-2100

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.